ISPOR Sixth Annual European Congress Scientific Awards Winners

2003-2004 ISPOR President Sean Sullivan, PhD congratulating the ISPOR 2003 Research Excellence Award Winner Jean-Michel Gaspoz MD

2003 ISPOR Research Excellence Awards
The recipients of the 2003 ISPOR Research Excellence Award (one for Methodology Excellence and one for Practical Application Excellence) are selected by the Awards Committee based upon publications that have appeared in respected peer-review journals and other communication venues (e.g., books, reports) during the preceding eighteen months from January 1 of the year awarded. The award selection is based upon the publication's clear description of methods, along with the appropriate and creative applications (or proposal thereof in conceptual methodology work) of techniques to answer important questions in the field of pharmacoeconomics and outcomes research. Such publications will be expected to have much impact on the field, due to their acceptance and application by others.

2003 recipient of the ISPOR Research Excellence Award for Practical Application Excellence
Jean-Michel Gaspoz MD as the senior author of the research paper:
“Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.” New England Journal of Medicine 2003;348:562-3
A Special thanks to Newell McElwee, PharmD, MSPH, Chair, previous ISPOR Research Excellence Award Task Force and his committee for selecting the Recipient!

ISPOR Best Contributed Podium Presentation Award

Best General Podium Presentations

HOSPITALIZATION RELATED TO ABUSE OF THE ELDERLY WITH DEMENTIA AND OTHER MENTAL HEALTH DISORDERS: RESOURCE USE AND COSTSHOSPITALIZATION RELATED TO ABUSE OF THE ELDERLY WITH DEMENTIA AND OTHER MENTAL HEALTH DISORDERS: RESOURCE USE AND COSTS
O’Brien JA1, Pitronak-Moore CA1, Caro JJ1, Jacobs LM2, 1Caro Research Istitute, Concord,MA, USA; 2University of Connecticut Medical School, Farmington, C, USA

ACARBOSE FOR THE PREVENTION OF TYPE II DIABETES IN CANADA: AN ECONOMIC EVALUATION
Gestisos D1, Caro JJ2, Caro I3, Klittick W2, O’Brien JA1, 1Caro Research Institute, Hammonds Plains, NS, Canada; 2Caro Research Institute, Concord, MA, USA; 3Caro Research Institute, Dorval, QC, Canada
PROSPECTIVE COHORT STUDY IN HIP FRACTURE : RISK AND ECONOMIC IMPACT OF VENOUS THROMBO-EMBOLIC COMPLICATIONS (VTE) IN REAL LIFE
Lingdren P1, Jonsson B2, Spiesser J1, Carita P1, Gabriel S3, 1Inst. Of Environmental Medicine, Karolinska Institutet, Uppsala, Sweden; 2Stockholm Health Economics, Stockholm, Sweden; 3Sanofi-Synthelabo Recherche, Bagneux, France
Best New Investigator Podium Presentations

COST-EFFECTIVENESS OF ANTIDEPRESSANT THERAPY, COGNITIVE BEHAVIOUR THERAPY AND THEIR COMBINATION FOR PEOPLE WITH BULIMIA NERVOSA IN THE UK
Simon J1, Whittington C2, 1The Eating Disorders Guideline Development Group OBO, Health Economics Research Centre, University f Oxford, Oxford, UK; 2National Collaborating Centre for Mental Health, National Institute for Clinical Excellence, London, UK

CLINICAL OUTCOMES AND COSTS OF DRUG ELUTING STENTS IN THE CARDIAC CATHERIZATION LAB
Sridhar K1, Gwadry-Sridar E2, 1University of Western Ontario, London, ON, Canada; 2McMaster University, London, ON, Canada

COST-EFFECTIVENESS OF ROSIGLITAZONE-METFORMIN COMBINATION IN OVERWEIGHT PATIENTS WITH TYPE 2 DIABETES IN GERMANY
Shearer A1, Bagust A1, Schoeffski O2, Reitberger U3, Goertz A4, Behrens MV5, 1University of York, York, UK; 2University of Erlangen-Nurenberg, Nuremburg, Germany; 3Kendle International Inc., Munich, Germany; 4GlaxoSmithKline, Munich, Germany; 5GlaxoSmithKline, Uxbridge, UK

Best Student Podium Presentations

Children with ADAH (Attention-Deflicit/Hyperactivity Disorder): Health Care Use and Social Burden on the Family
De Ridder A1, De Grave1, Adriaenssen I2, 1University of Antwerp, Antwerpen, Belgium; 2Johnson & Johnson Pharmaceutical Services, Beerse, Belgium
Type of Diabetes and Adherence to Self-Monitoring of Blood Glucose (SMBG)
Vince G, Barner JC, Lopez DA, University of Texas at Austin, Austin, TX, USA

ISPOR Best Contributed Poster Presentation

Best General Podium Presentations

ECONOMIC EVALUATION OF THE MEDENOX (PROPHYLAXIS IN MEDICAL PATIENTS WITH ENOXAPARIN) TRIAL FROM THE PERSPECTIVE OF HOSPITALS IN GERMANY: RESULTS OF A SUBGROUP ANALYSIS
Schadlich PK1, Kentsch M2, Weber M3, Kammerer W4, Nadipelli V5, Huppertz E6, Brecht JC, 1Informed Gmbh—Outcomes Research & Health Economics, Ingolstadt, Bavaria, Germany; 2Clinics of Itzehoe, Itzehow, SH, Germany; 3Clinics of the City of Cologne, Cologne-Merheim, NRW, Germany; 4Dr-Horst-Schmidt-Clinics, Wiesbaden, Hesse, Germany; 5Aventis Pharmaceuticals,Bridgewater, NJ, USA, 6Aventis Pharma Deutschland, Bad Soden am Taunus, Hesse, Germany

AN EVIDENCE-BASED APPROACH PROVIDES A QUANTITATIVE ASSESSMENT OF THE EFFICACY OF ESOMEPRAZOLE FOR HEALING OF EROSIVE ESOPHAGITIS BASED ON DISEASE SEVERITY
Johsnon DM1, Roach A2, Traxler BM2, Levine D2, 1Eastern Virginia School of Medicine, Norfolk, VA, USA; 2AstraZeneca LP, Wilmington, DE, USA

COMPARISON OF THE PERFORMANCE AND DATA QUALITY OF ELECTRONIC AND PAPER DIARIES FOR BENIGN PROSTATIC HYPERPLASIA (BPH)
Bushnell DM1, Martin ML1, Hareendran A2, Abraham L2, 1Health Research Associates, Inc, Mountain Lake Terrace, WA, USA; 2Pfizer Ltd., Sandwich, UK

Best New Investigator Podium Presentations

HEALTH ECONOMIC EVALUATION OF A NEW CONTRAST PRODUCT FOR LIVER MRI IN COLORECTAL CANCER PATIENTS
Waire H1, Annemans2, L, Mueller U3, 1HEDM, Meise, NA, Belgim; 2Ghent University, HEDM, Meise, NA, Belgium; 3Schering AG, Berlin, Germany
EVALUATION OF ANTIDEPRESSANT MEDICATION ADHERENCE IN A NOT FOR PROFIT HEALTHCARE ORGANIZATION
Alison LM1, Wong SL2, Day D3, 1Healthfirst, Inc., New York, NY, USA; 2Pfizer, Inc., Syosset, NY, USA; 3Pfizer, Inc., New York, USA

COMPARING THE PROVIDER TIME AND COSTS FOR RED BLOOD CELL TRANSFUSIONS IN ANAEMIA MANAGEMENT OF CANCER PATIENTS USING THE ACTIVITY-BASED COSTING (ABC) METHOD IN A FRENCH AND AUSTRIAN SETTING
Van Bellinghen L1, De Cock E2, Piedbois P3, Sevelda P4, Sevelda F3, 1Amgen Health Economics Europe, Brussles, Belgium; 2MEDTAP International, London, United Kingdom; 3CHU Henri Mondor, Creteil-aris, France; 4General Hospital, Vienna, Austria

A special thanks goes to all the judges, the ISPOR Annual European Congress Awards Task Force Chair as well as the ISPOR Awards Committee Chair who volunteered their time and efforts in selecting the winners.

ISPOR ANNUAL EUROPEAN CONGRESS AWARDS TASK FORCE CHAIR:
Jenifer Ehreth PhD – Medtronic Europe Sa

ISPOR JUDGES:
Stephen Beard, RTI Health Solutions; Stephane Roze, Core Center for Outcomes Research; Marlene Gyldmark, MCs, MPhil, Hoffman La Roche; Rukmini Rajagopalan, Takeda Pharmaceuticals North America, Inc.; Pascale Brasseur, MS, Serono International SA; Olaf Pirk, Fricke & Pirk GmbH; Monia Marchetti, MD, IRCCS POLICLINICO SAN MATTEO; Mason Russell, MAPE, Biogen, Inc.; Judy O'Brien, RN, BSPA, Caro Research Institute; Judith Baker, PhD, CPA, Marko Mychaskiw, PhD, CPA, Purdue University; James Jarrett, MA, Cambridge Genetics; Frank-Ulrich Fricke, Fricke & Pirk GmbH; Josef Georg Brecht, InForMed GmbH; Anthony Lockett, PhD, MD, DMS; Covance; Angela Christie, Aventis; Rami Ben-Jospeh, Health Process Mgmt.; Donald Bushnell, MA, Health Research Associates, Inc.; Otto Wolke, RPh, Schellen & Partners USA, Inc.; Pamela Aidelsburger; Catherine Brun, Pharma Novartis; Mona Martin, RN, MPA; Health Research Associates, Inc., Sue Ellen Kline, PhD, MS, IMS Health; Talat Ashraf, MD, MS, Abbott Labs; Lynda Bryant, GlaxoSmithKline; Andrew Peterson, PharmD, University of the Sciences Philadelphia; Michael Iskedjian, RPh, MSc; PharmIdeas Research & Consulting Inc.; Liviu Niculescu, MD, MPP, MPH, Pfizer, Inc.; Victor Kiri, MSc, PhD, GlaxoSmithKline; Karen L. Rascati, RPh, PhD, University of Texas; Maarten Postma, PhD, University of Groningen; Hans-Peter Dauben, MD, DIMDI; Diego Ossa, Oxford Outcomes; Gilles Berdeaux, MD, Laboratoires Alcon France; Trond Haider, Amersham Health; Isabelle Girod, MSc, Mapi Values; J.Bos, MSc, Netherlands Vaccine Institute; Kjeld Christensen, MSc, AstraZeneca, DA; Michael Christensen, MSc, Novo Nordisk, A/S; Maria Koltowska-Haggstrom, MD, Pharmacia AB; Michael Happich, GSF; Manolis Karamalis, Novo Nordisk; Olga Sanchez-Solino, MD, Biogen Iberia, S.L.; Ruth Whittington, MS, Rx Communications Ltd.; Saso Delinikolov, Novo Nordisk; Linda Davies, MS; University of Manchester, JRBJ; Brouwers, PhD, State University & Roningen, Kirsten Long, PhD, Mayo Clinic; Christel Naujoks, NOVARTIS PHARMA AG; Linda Abetz, MA, Mapi Values; Klaus Hieke, NEOS Health AG; Carmen Dirksen, PhD, University Hospital Maastricht; Barbara Schramm, MERG; John E. Paul, PhD, RTI Health Solutions; Abraham G. Hartzema, PhD, PharmD, MSPH, Pharmacy Health Care Adminstration; Cammy Yuen, Janssen-Cilag; Karen Moeremans, MD, HEDM; Maria Geitona, University of Thessaly; Patrick Mollon, MD, MBA, MSc, Pfizer, Inc.; Marion Schaefer, Humboldt-Universität; Robert Welte, GSF; Alexander Bykov, Sanofi-Synthelab; Nancy Vanoverbeke, MSc, HEDM; Jacek Ruszkowski, WSPiZ; Martin Backhouse, Novartis Pharma AG; Manuela Joore, PhD; University hospital Maastricht; Andreas Ruppert, BMS.


Best Poster Award recipient DM Bushnell	New Investigator Poster Award recipient Laura-Anne van Bellingham	Best Student Podium Award recipient Gabor Vince

Best Student Podium Award recipient A. De Ritter	Best New Investigator Podium Award recipient Judit Simon	Best Podium Award recipient Judy O’Brien